Pinned Tweet
Cancer prevention fails when infrastructure can’t support longitudinal care. When high-risk patients must leave their health system for “routine” prevention, that’s a systems signal.
In hematologic malignancy precursor states (e.g. MGUS, smoldering myeloma), prevention requires embedded biobanking, defined surveillance pathways, and realistic capacity planning. pmc.ncbi.nlm.nih.gov/article…
These are catchment & shared-resource issues. Prevention cohorts depend on reliable surveillance access, stable accrual pipelines, and biobanks integrated into clinical operations. When access breaks, accrual breaks—and prevention science stalls
It’s that ASH time of year when I try to impress on people how stunning progress has been in the blood cancer field. My entire career AL amyloidosis has been a death sentence. Not anymore.
I wish the AI biobros all the best but medical miracles are not 10 years in the future—they are here now.
Can AL amyloidosis be cured?
Dr. Meletios Dimopoulos at #ISA2026: functional cure = no relapse ≥5 yrs after hemCR, no salvage, no cardiac/dialysis-requiring renal progression. Low clone burden, early deep response and MRD negativity define this group. #mmsm
@ISA_Amyloidosis
12
932
Michael H. Tomasson, MD retweeted
Saturation barcoding of ribosomal DNA resolves the nucleolar organizer regions of the human genome
biorxiv.org/content/10.64898…
Michael H. Tomasson, MD retweeted
Abstract 825 (Guan): Dara-Ven-Dex as frontline therapy for t(11;14) AL amyloidosis. Phase 2 study of 38 patients with 10.9 months follow-up. The 3-month CR/VGPR rate was 89%! Best cardiac response was 71% and renal response 80%. 3 cardiac deaths in the first 3 months.
My take: I’d much prefer this option for t(11;14) AL amyloidosis over Dara-CyBorD. I like this even over a potential BsAb for more frail patients.
Michael H. Tomasson, MD retweeted
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies - goo.gl/alerts/jYXt8d #GoogleAlerts
Michael H. Tomasson, MD retweeted
I invite you to enjoy a recent podcast that I recorded that discussed mechanisms for CVD on diabetes. Mins 1:48-3:00, and then minute 30:00 to the end, although I would encourage listening to the whole thing!
diabetesbio.libsyn.com/insul…
Michael H. Tomasson, MD retweeted
Are we curing patients with r/r DLBCL using BsAb monotherapy beyond 2L?
#ASH26
5-year outcomes with glofitamab:
• DoCR: 46%
• 5-year PFS: 19.3%
• 5-year OS: 28.1%
Perhaps the most democratic form of innovation in lymphoma: potentially curative, off-the-shelf, and not dependent on CAR-T infrastructure!
Michael H. Tomasson, MD retweeted
Masterclass at #ISA2026: @scheinbp reviewed current AL therapy. Take-homes: Dara-VCd is frontline standard (5-yr OS benefit); adapt to organ vulnerability; ASCT role in dara era unresolved; venetoclax/BCMA active at relapse. #mmsm @ISA_Amyloidosis
I missed this. The race to cure all diseases starts now!! Or…next year when the tissue culture hoods get delivered!!
thecrimson.com/article/2026/…
3
226
Someone tell @DarioAmodei he was too slow
1/ The era of 3 years of intensive chemo for adult ALL is ending. Highlights from Dr. Hagop Kantarjian @DrHKantarjian @UTMDAnderson (MD Anderson) at Louisville Hematology Highlights 🧵 #leusm
2/ Ph+ ALL: ponatinib + blinatumomab is the new standard. In ~110 pts: CR 96%, NGS-MRD neg 95%, 5-yr OS ~90%. Transplant is rarely needed. A randomized NEJM trial confirms it: EFS 86% vs 67%. Consider stopping the TKI after ≥5 yrs of PCR- and NGS-MRD negativity.
3/ Ph– B-ALL: half the chemo (8→4 cycles), plus blinatumomab + inotuzumab, with maintenance cut to ~15 mo. 5-yr OS ~90% up to age 60. Transplant only for the highest-risk genomics.
4/ CAR-T belongs in remission or MRD, not active disease. Track NGS-MRD in everyone: even 5 cells per million predicts relapse. And don't ignore the data coming out of China.
5/ On evidence: when the curves are so far apart that "a truck drives through" them, there's no equipoise. Then waiting a decade for a randomized trial has a cost for patients.
Watch the full talk: youtu.be/v5NbU3qlBa4?is=uHfR…
260
Michael H. Tomasson, MD retweeted
7/10 MajesTEC-5 (Arm G): Frontline trispecific ramantamig + Dara/Len hits 100% ORR & 100% MRD-neg (10^-5) by C3 in TE-NDMM.
Michael H. Tomasson, MD retweeted
5/10 NEXICART-2: NXC-201 CAR-T delivers 100% ongoing CR (>12m f/u) & 100% cardiac/renal responses in RR AL amyloidosis.
Michael H. Tomasson, MD retweeted
As #ASH26 approaches, I’m bringing back my classic series of tweets highlighting abstracts that matter to physicians working in “the land of NO CAR-T cells.” Because years go by, but some things never change…
























